Illumina, Inc.
Illumina, Inc. (ILMN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ilmn · pe ratio · data through Dec 28, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Illumina, Inc. (ILMN) measures how much investors pay for each dollar of the company's trailing earnings. ILMN's current PE ratio of 29.11x is calculated by dividing its stock price of $158.80 by its TTM earnings per share of $5.58. −47.3% discount vs 5Y avg 55.2x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-28
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 16 fiscal years · Front-end computedMinQ1 · 25%51.3x
MedianQ3 · 75%107.3x
Max
At 29.11x, ILMN's current P/E is lower than in 6% of its annual fiscal year readings over the past 16 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Illumina, Inc.You ILMN | $24.0B | 29.11x | -7.2% | $5.58 |
 Quest Diagnostics Incorporated DGX | $22.0B | 19.42x | -38.1% | $8.94 |
 Genmab A/S GMAB | $15.3B | 19.86x | -36.7% | $1.55 |
 Hologic, Inc. HOLX | $17.0B | 26.99x | -14.0% | $2.49 |
 ICON Public Limited Company ICLR | $11.4B | 62.31x | +98.5% | $2.92 |
 Labcorp Holdings Inc. LH | $21.6B | 23.81x | -24.1% | $10.53 |
 Medpace Holdings, Inc. MEDP | $12.9B | 35.91x | +14.4% | $15.64 |
Industry Average 6 peers with valid PE | — | 31.39x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-28Latest FY2025 | 24.52x | $5.48 | — | |
2024-12-29 FY2024 | — | $-7.69 | — | |
2023-12-31 FY2023 | — | $-7.35 | — | |
2023-01-01 FY2023 | — | $-28.05 | — | |
2022-01-02 FY2022 | 72.86x | $5.08 | -9.0% | |
2021-01-03 FY2021 | 80.09x | $4.46 | +71.2% | |
2019-12-29 FY2019 | 46.78x | $6.82 | -9.8% | |
2018-12-31 FY2018 | 51.87x | $5.62 | +21.5% | |
2017-12-31 FY2017 | 42.70x | $4.97 | +8.0% | |
2016-12-31 FY2016 | 39.54x | $3.15 | -32.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Illumina, Inc. (ILMN) measures how much investors pay for each dollar of the company's trailing earnings. ILMN's current PE ratio of 29.11x is calculated by dividing its stock price of $158.80 by its TTM earnings per share of $5.58.
Frequently asked questions
ILMN pe ratio · 6 questionsILMN's current PE ratio is 29.11x as of 2026-06-08, based on a stock price of $158.80 and TTM EPS of $5.58. Data sourced from Financial Modeling Prep via ILMN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Illumina, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08